linked glycosylation ofg30K, which suggests that g30K may be modified by addition of N-linked oligosaccharides and that the amino acid sequence may contain Asn-X-Ser or Asn-X-Thr. The g30K was also purified on an immunoadsorbent column consisting of MAb CH-A9 linked to Sepharose 4B and was shown to be an HSV-2 type-specific antigen by indirect ELISA. The glycoprotein could induce HSV-2 type-specific neutralizing antibody in BALB/c mice. This evidence suggests that g30K may be a novel glycoprotein of HSV-2.
Introduction
At least seven glycoproteins of herpes simplex virus (HSV) have been positively identified in infected cells: gB, gC, gD (Spear, 1976) , gE (Baucke & Spear, 1979) , gG (Marsden et al., , 1984 Roizman et al., 1984) , gH and gI (McGeoch et al., 1985; Longnecker & Roizman, 1987) . Most of the glycoproteins can induce neutralizing antibodies and cellmediated immunity in animals (Marsden, 1987) . The complete DNA sequence of HSV-1 strain 17 syn ÷ has been determined. There are 72 genes which encode 70 distinct proteins in the whole genome of HSV-1 (McGeoch et al., 1988) . Despite numerous studies of the HSV glycoproteins and their genes, some glycoproteins specified by HSV-1 or HSV-2 remain undetected.
In the course of screening monoclonal antibodies (MAbs) to HSV-1 or HSV-2, we identified an HSV-2 type-specific MAb, CH-A9, which precipitated a glycoprotein in HSV-2-infected cell extracts, and mapped the gene location of the target antigen of MAb CH-A9. We purified the glycoprotein reactive with MAb CH-A9 and tested its ability to induce neutralizing antibody production in mice. The studies reported here suggest that the target antigen of MAb CH-A9 may be a novel HSV-2 glycoprotein.
Methods

Cells and viruses. Baby hamster kidney (BHK) cells (clone 13) and
Vero cells obtained from Institute of Epidemiology, Academy of 0001-0775 © 1992 SGM Military Medical Sciences, Beijing, China, were grown in 199 medium (Gibco) supplemented with 10~ newborn calf serum (NCS). HSV-1 strain SM44 was from Chengdu Institute of Biological Products; HSV-2 strain Say was from Beijing Institute of Biological Products. HSV-I strain 17 syn +, HSV-2 strain HG52 and HSV-1-HSV-2 intertypic recombinants were obtained from Dr Howard Marsden, MRC Virology Unit, Institute of Virology, University of Glasgow, U.K. The genome structures of the recombinants have been reported previously (Chartrand et al., 1981; Davison et at., 1981; Hope et al., 1982; Marsden et al., 1978 Marsden et al., , 1982 Preston et al., 1978; N.D. Stow, personal communication) .
MAbs. Hybridoma cell lines secreting MAbs to HSV were established. CH-A9 and CM-D3 are HSV-2 type-specific MAbs (Gao et al., 1985 a) and 1A 12, 2C5, 2D11 and 1D 10 are type-common (Gao et al., 1985b) . All the MAbs were identified by indirect ELISA and immunofluorescence (IF) tests. MAb 1001 against HSV gC was the generous gift of Dr Anne Cross, MRC Virology Unit, Institute of Virology, University of Glasgow, U.K. The Sp2/0 myeloma ascites and supernatant fluid were also used. MAb G4 to haemorrhagic fever with renal syndrome (HFRS) virus was kindly supplied by Dr An Xian-lu of this department.
Sera of mice or rabbits against HSV-1 or HSV-2. Vero cells infected
with HSV-1 strain SM44 or HSV-2 strain Sav were injected into mice or rabbits four times at 1 week intervals. At day 7 after the final injection the sera were tested for anti-HSV antibodies by ELISA. The ELISA titres of the sera were all 10 -5 and the sera were stored at -30 °C for use.
IF test.
Monolayers of BHK cells grown on 1.5 x 0.5 cm glass slides in 90 ml cell culture flasks were infected with HSV strains. When the infected cells displayed a 3 + c.p.e., one-half of the slides were fixed in cold acetone for 10 min for indirect IF staining (Gao et al., 1985a) . The other half of the unfixed slides was used for the cell membrane IF tests. MAb CH-A9 in 199 medium containing 2~ NCS was added to the slides and then incubated at 4 °C for 1 h. After washing three times with 0-01 M-PBS pH 8-0, the slides were incubated with fluorescein isothiocyanate-labelled rabbit anti-mouse lgG antibody diluted with 0-01% Evans' Blue at 37°C for 30 min, washed and dried. IF was detected with a fluorescence microscope (AO, U.S.A.).
Preparation of cell membrane extracts from HSV-infected BHK cells.
Monolayers of BHK cells were infected with HSV-1 strain SM44 or HSV-2 strain Sav and incubated at 37 °C for 18 to 24 h. The infected cells were scraped and washed three times by centrifugation at 1000 r.p.m, for 10 min in 0.01 M-PBS pH 8-0. The pellet was resupended in 0-1 M-glycine-NaOH buffer pH 8.8, and the suspension was then sonicated. After centrifugation at 2000 r.p.m, for 10 rain, 1% Triton X-100 (Cart Roth KG Chemische) was added to the supernatant and incubated at 37 °C for 30 min. The mixture was centrifuged at 100000g for 1 h and the supernatant was used for affinity chromatography. The cell membrane extracts from uninfected BHK cells were prepared by the same method.
Affinity chromatography. Three grams of CNBr-activated Sepharose 4B (Pharmacia) was washed according to the manufacturer's instructions and combined with 94 mg of MAb CH-A9 y-globulin in 10 ml of buffer containing 0-1 M-NaHCO 3, 0.5 M-NaCI, pH 8-5 at 4°C overnight. The immunoadsorbent was blocked with 1 M-ethanolamine pH 9.0 for 2 h and washed with three cycles of alternating pH. Each cycle consisted of a wash with 0.1 M-acetate buffer containing 0.5 MNaCI pH 4.0 followed by a wash with 0-1 M-borate buffer containing 0.5 M-NaCI pH 8-0. The mixture was equilibrated at 4 °C with the washing buffer (0.1 M-Tris-HCI pH 8-0). The cell membrane extracts, prepared from either HSV-1-or HSV-2-infected or uninfected BHK cells, were loaded onto the immunoadsorbent column and recycled through the column five times. The column was washed extensively with washing buffer until the absorbance value at 280 nm was 0.05, then eluted with 3 M-KCNS pH 8.0. The KCNS fraction was collected in 3 ml fractions until the A 280 was 0.05. The MAb CH-A9 target antigen from the eluate was dialysed extensively against 0.01 M-PBS pH 8.0, then concentrated by dialysing against sucrose.
ELISA. Two methods were used to coat HSV antigen on 40-well polystyrene microplates (Tianjin Plexiglass Factory). (i) After scraping HSV-infected BHK cells into 0.01 M-PBS pH 8.0, 100 ~1 of the cell suspension, 106 ceils per ml, was added to each well. The cells were pelleted by centrifugation at 1600 r.p.m, for 15 min. The supernatant was then removed and the plates were dried. The cells absorbed to the well bottom were fixed with cold methanol:acetone (1:1) for 10 min and the plates were dried again and stored at -30 °C for use. (ii) The plates were coated with MAb CH-A9 target antigen from the elution diluted in 0-05 M-sodium carbonate buffer pH 9.6 at 4 °C overnight. The plates were washed three times with ELISA washing buffer containing per litre 0-2 g of KH2PO,, 2-9 g of Na2HPO,. 12H20, 0.2 g of KCI, 8-0 g of NaCI, and 0.5 ml of Tween 20. One-hundred microlitres of diluted antibodies was added to each well, and the plates were incubated in a humid chamber at 37 °C for 1 h, then washed three times with the ELISA washing buffer. After incubation with 100 gtl of horseradish peroxidase-labelled rabbit anti-mouse IgG antibody per well at 37 °C for l h, the unbound enzyme conjugate was removed by washing three times with the ELISA washing buffer. One-hundred microlitres of substrate o-phenylenediamine-H20 2 in phosphoric acid buffer was then added into each well for incubation at 37 °C for 15 min. Radiolabellingprocedures. Monolayers containing 4 x 106 BHK cells were exposed to 0.5 TCIDso/0-I ml of HSV-2 strain Say per cell or virus-free maintenance medium (199 medium supplemented with 2~ NCS). After adsorption at 31 °C for 3 h in maintenance medium, the monolayers were washed three times with PBS and incubated for a further 16 to 20 h in leucine-free Eagle's MEM containing 13 ~Ci/ml of [3H]leucine or glucose-free MEM containing 10 ~tCi/ml D-[14C]fructose (Institute of Radiomedicine, Chinese Academy of Medicine). MAb CH-A9 target antigen from the 'HSV-2' eluate was labelled with 1251 according to Greenwood & Hunter (1963) .
Addition oftunicamycin. Monolayers of BHK cells were infected with 0.5 TCID5o/0.1 ml of HSV-2 strain Sav per cell. After adsorption at 31 °C for 3 h, the monolayers were washed three times with PBS and incubated for a further 16 to 20 h in glucose-free MEM containing 13 p.Ci/ml of [3H]glucosamine or methionine-free MEM containing 2 IICi/ml of [35S]methionine" Both of the maintenance media contained 2 ~tg/ml of tunicamycin (Sigma).
Preparation of infected cell extracts. Infected cells showing a 4 + c.p.e.
were harvested. The monolayers were washed three times with TNP buffer containing 0-1 M-Tris-HC1 pH 7-4, 0-15 M-NaCI, 0-1 mM-PMSF and 0.02~ sodium azide. After scraping of the cells into TNP buffer they were washed three times with TNP buffer by centrifugation at 3000 r.p.m, for 5 min, resuspended in TNP buffer containing 1 ~ NP40 and incubated for 2 h at 4 °C. After centrifugation at 1000 r.p.m, for 10 rain, the supernatant was used for either electrophoresis or immunoprecipitation. The cell extracts were boiled for 5 min with sample buffer containing 2.3% SDS, 5~ 2-mercaptoethanol before electrophoresis.
Immunoprecipitation. One-hundred microlitres of labelled infected cell extracts and 20 lal of MAb CH-A9 ascites were incubated overnight at 4 °C and 20 gl of rabbit anti-mouse IgG antibody was added for further incubation at 4 °C for 2 h. The antigen-antibody complex was precipitated by the addition of 100 ~tl of a 10~ suspension of Staphylococcus aureus and further incubation for 2 h at 4 °C. After centrifugation of the mixture at 14000 r.p.m, for 10 min, the pellet was resuspended and washed three times by centrifugation at 14000 r.p.m. for 10 rain in TNP buffer containing 0.25~ NP40. The pellet was resuspended with the sample buffer for further incubation at 4 °C for 1 h. After centrifugation at 10000 r.p.m, for 10 min, the supernatant was boiled for 5 rain. Neutralization test. MAb CH-A9 target antigen from elution (g30K) was mixed with complete Freund's adjuvant (CFA) and injected into eight female BALB/c mice five times (10 lag per time) at 3 week intervals. Eight female BALB/c mice of the control group were injected with normal saline (NS) and CFA. At days 7 and 14 after the final injection the sera were tested for neutralizing antibodies. The ability of each mouse serum and MAb CH-A9 to neutralize HSV-1 or HSV-2 was examined by preincubating 100 TCID50 of HSV-1 strain SM44 or HSV-2 strain Sav with a series of twofold dilutions of each mouse serum or MAb CH-A9 in the presence of complement (mixture of fresh sera from three guinea-pigs) at a final dilution of 1:30 or without complement, in a total volume of 75 btl in 96-well microtitre plates (Nunc), for 1 h at 37 °C. Fifty microlitres of BHK cell suspension (2 x 106 ceils per ml) in 199 medium supplemented with 10~ NCS was added to each well. Virus and uninfected BHK cell control groups were included. The plates were incubated at 37 °C and c.p.e, was observed daily. The 50% serum neutralizing endpoint was calculated according to K~.rber's method. (Tables 1 and 2 ). These tests gave the same results. Table 2 shows that M A b s C H -A 9 and C M -D 3 are HSV-2-specific antibodies, which react with HSV-2 strains Sav or HG52, but not with HSV-1 strains SM44 or 17 syn + or uninfected B H K cells. HSV-infected B H K cell m e m b r a n e I F tests indicated that the target antigen of M A b C H -A 9 was on the HSV-2-infected B H K cell m e m b r a n e (Table 1) . F r o m Table 2 , we also find that M A b Mad-2 is an HSV-l-specific antibody and M A b C M -D 3 is another HSV-2-specific antibody. Previous studies (Gao et al., 1986) found that almost all of the H S V 
PAGE and autoradiography.
Immunoprecipitation with anti-HSV MAbs
M A b C H -A 9 immunoprecipitated a glycoprotein with an apparent Mr o f 30K which was a distinct species, based on isotopic labelling and mapping experiments. The reaction o f C H -A 9 with extracts from HSV-2-infected B H K cells are shown in Fig. 1, Fig. 2 and Fig. 4 . The HSV-2 strain Sav-infected B H K cells were labelled with [3H]leucine (Fig. 1) or with [14C]fructose (Fig. 2) or with [3H]glucosamine (Fig. 4) and the extracts were prepared as described. In Fig. 1 and Fig. 4 , lanes I show a polypeptide profile of HSV-2-infected B H K cells. M A b C H -A 9 reacted with a 30K polypeptide (lane 2) but Sp2/0 ascites did not precipitate any polypeptide (lane 3). In Fig. 2 with any peptide in the extracts o f HSV-l-infected B H K cells (Fig. 3) . extracts of HSV-2-infected B H K cells (Fig. 2) . In Fig. 2 and Fig. 3 , M A b 1A12 precipitated a 105K glycoprotein and M A b 1D 10 precipitated a 60K glycoprotein from the extracts of HSV-1-or HSV-2-infected B H K cells. Sp2/0 ascites did not react with any peptide (Fig. 2 and Fig. 3 ). The polypeptide profiles of the extracts of HSV-1-or HSV-2-infected B H K cells labelled with [14C]fructose were included as controls ( Fig. 2 and Fig. 3 ).
Physical mapping of the target antigen of MAb CH-A9
We attempted to m a p the coding region for the M A b C H -A 9 target antigen by examining the ability o f C H -A9 to react with a series of H S V -1 -H S V -2 intertypic recombinants. The E L I S A and I F tests gave the same results. The data ( the gC coding region. Since its Mr is smaller t h a n that of gC, the glycoprotein m a y be a modified form of gC (Qin et al., 1989) . M A b Mad-2 or C M -D 3 precipitated a 130K
glycoprotein from extracts of HSV-1-or HSV-2-infected 1D10 precipitated a 60K glycoprotein from extracts of HSV-1-or HSV-2-infected B H K cells a n d the genome location of its target antigen is in the u n i q u e short (Us) region at m.u. 0-912 to 0-976 which overlaps the large region coding for gD, gE and gI. Since its Mr is the same as that of gD, the target a n t i g e n of M A b 1 D 10 may be gD (Yu et al., 1991) . Table 3 shows the properties of the target antigen of the M A b s used in this test.
Effect of tunicamycin on the MAb CH-A9 target antigen
The M A b C H -A 9 target antigen was affected by the glycosylation inhibitor t u n i c a m y c i n . M A b C H -A 9 precipitated a 30K glycoprotein from extracts of HSV-2-infected B H K cells in M E M c o n t a i n i n g [3H]glucosamine (Fig. 6, lane 4) . This suggested that [3H]glucosamine can permeate into HSV-2-infected BHK cells. MAb CH-A9 did not precipitate any peptide from extracts of HSV-2-infected BHK cells in MEM containing [3H]glucosamine and tunicamycin (Fig. 6, lane 3) . Thus, it appeared that [3H]glucosamine could not permeate into HSV-2-infected BHK cells when tunicamycin was present in the medium and that the MAb CH-A9 target antigen (g30K) might mainly contain N-linked oligosaccharides, since tunicamycin is an N-glycosylation inhibitor. We did not observe that tunicamycin affected the Mr of the MAb CH-A9 target antigen. MAb CH-A9 precipitated a 30K peptide from extracts of HSV-2-infected BHK cells in MEM containing [35S]methionine and tunicamycin or tunicamycin-free MEM (Fig. 7, lanes 4 and 3) . Hence the number of N-linked oligosaccharides of the MAb CH-A9 target antigen might not be large.
Elution from the immunoadsorbent column and the properties of the MAb CH-A9 target antigen from the elution
Cell membrane extracts prepared from either HSV-1 strain SM44 or HSV-2 strain Sav or uninfected cells were loaded onto an immunoadsorbent column consisting of MAb CH-A9 linked to CNBr-activated Sepharose 4B. The column was eluted with 3 M-KCNS. A peak on the elution curve of the membrane extracts prepared from HSV-2-infected BHK cells could be observed but was not seen on the elution curves of the membrane extracts prepared from HSV-1-infected or uninfected BHK cells (Fig. 8) . In ELISA, the MAb CH-A9 target antigen from the HSV-2 eluate reacted with mouse anti-HSV-2 sera and MAb CH-A9, but did not react with mouse anti-HSV-1 sera, another anti-HSV-2 type-specific MAb CM-D3, anti-HSV type-common MAbs 1A12, 2C5, 2D1 l, anti-HFRS virus MAb G4, or the ascites of the Sp2/0 myeloma cell line (Table 4 ). The Mr of the MAb CH-A9 target antigen from the HSV-2 eluate (30K) was determined by electrophoresis of the eluate labelled with 1251 on SDS-PAGE (Fig. 9, lane 2) . This result was the same as that of the immunoprecipitation (Fig. 1, 2 and 4). The band pattern of HSV-2-infected BHK cells labelled with [3H]leucine on SDS-PAGE was developed by autoradiography (Fig. 9, lane 1) .
Ability of MAbs and sera of mice, immunized with MAb CH-A9 target antigen, to neutralize HSV-1 or HSV-2
Groups of 8-week-old BALB/c female mice were immunized with the MAb CH-A9 target antigen from the HSV-2 eluate on five occasions. Mice were injected i.h. with 10 ~tl of the antigen in CFA at 3 week intervals. Control mice were injected with NS and CFA. At days 7 and 14 after the final injection the sera of the mice and MAb CH-A9 were tested for their ability to neutralize HSV-1 or HSV-2 by a micro-ceU culture neutralization test with or without the presence of complement. The 50~ neutralizing endpoints (X) of the sera against HSV-2 were 1:55 and 1:69, respectively. There was no neutralization activity against HSV-1. The sera of the control mice had no neutralization activity against HSV-1 or HSV-2 (Table 5 ). The ability of MAbs CH-A9, Mad-2, ID10, 1A12 and 2C5 to neutralize HSV-1 and HSV-2 was variable (Table 6 ). The neutralizing titres of MAb CH-A9 against HSV-2 were 1:128 and 1:25600 with or without complement, respectively. However, MAb CH-A9 had no neutralization activity against HSV-1 whether with or without complement. The ascites of Sp2/0 myeloma had no neutralizing effect against HSV-1 or HSV-2 (Table 6 ). The results suggest that the MAb CH-A9 target antigen may be a neutralizing antigen induced specifically by HSV-2.
Discussion
The data presented in this report suggest that a novel HSV-2 glycoprotein may be identified and characterized by using the HSV-2 type-specific MAb CH-A9, which was identified by its reactivity with a group of HSV reference strains and HSV isolates from patients in Xian, China. [DH] glucosamine, we found that the target antigen of MAb CH-A9 was a glycoprotein of HSV-2 (g30K). Tunicamycin, a glycosylation inhibitor, effectively inhibits N-linked glycosylation of gDOK. This fact suggests that gDOK may be modified by addition of N-linked oligosaccharides and the amino acid sequence may contain Asn-X-Ser or Asn-X-Thr (Spear, 1985) .
The gene for gDOK was mapped in the L component between coordinates 0.490 and 0.564 by analysis of the reactivity of MAb CH-A9 with HSV-1-HSV-2 intertypic recombinants. The DNA sequence of the UL region in the HSV-1 genome has been completed and this region includes two large open reading frames (UL36 and UL37) and a smaller one (UL38) encoding a virion protein of 50K (McGeoch et al., 1988; Pertuiset et al., 1989) . So far, HSV-2 DNA sequence analyses have been limited to individual genes or parts of genes. The total number of genes in the HSV-2 genome remains uncertain. The genes encoding gD, gE and gG of HSV-2 are all located in the Us region (Marsden, 1987; Watson, 1983) . The gene encoding gC-2 was mapped to the UL region of the viral genome from 0-62 to 0-64 m.u. (Zezulak & Spear, 1984) and has been sequenced (Swain et al., 1985) . The gene encoding gB was localized to the UL region from 0.348 to 0.366 m.u. and the sequence of the genes encoding gB-1 and gB-2 is also known (Bzik et al., 1984 (Bzik et al., , 1986 Stuve et al., 1987) . In the HSV-2 genome, the region from 0.533 to 0.583 m.u. contains a gene encoding the infected cell protein 32 (ICP32) and virion protein 19c (VP19c) (Yei et al., 1990) . Therefore the gene encoding g30K may be between coordinates 0.490 and 0.533, and it is necessary to sequence the gene encoding gDOK.
A series of HSV glycoproteins appears to be involved in both humoral and cell-mediated immune responses (Marsden, 1987; Spear, 1985) . The current investigations show that MAb CH-A9 has neutralization activity against HSV-2 and that purified g30K can induce neutralizing antibodies against HSV-2 in mice. These facts suggest that g30K may be a neutralizing antigen of HSV-2 and that g30K may be a potential candidate for a subunit vaccine against herpetic infections. Further study of this glycoprotein is required to determine its antigenic and biochemical properties. We are grateful to Dr H. S. Marsden for providing the HSV-I-HSV-2 intertypic recombinants and many materials concerning HSV glycoproteins. We also thank Dr Marsden for helpful advice and for carefully reading and modifying the manuscript. Thanks are also due to Dr U. Desselberger for bringing the recombinants to China and helpful discussion, and to Dr A. Cross for providing the MAbs against HSV gC.
